statement Co-amplification of MDM2 and CDK4 generates dedifferentiated liposarcoma in transformed human bone marrow stem cells in vitro and in vivo. Abstract Amplification and overexpression of MDM2 and CDK4 are well-known diagnostic criteria of well-differentiated liposarcoma (WDLPS)/dedifferentiated liposarcoma (DDLPS). Although it was reported that depletion of MDM2 or CDK4 decreased proliferation in DDLPS cell lines, it remains unclear whether MDM2 and CDK4 induce WDLPS/DDLPS tumorigenesis. We examined whether MDM2 and/or CDK4 produce WDLPS/DDLPS using transformed human bone marrow stem cells (BMSCs), 2H and 5H, with five oncogenic hits (overexpression of hTERT, TP53 degradation, RB inactivation, c-MYC stabilization, and overexpression of HRAS v12 ). In vitro functional experiments revealed that co-overexpression of MDM2 and CDK4 plays key roles in tumorigenesis by increasing cell growth and migration and inhibiting adipogenic differentiation potency compared to sole expression of MDM2 or CDK4. Using mouse xenograft models, we found that co-overexpression of MDM2 and CDK4 in 5H cells with five additional oncogenic mutations can develop proliferative DDLPS in vivo. Our results suggest that co-overexpression of MDM2 and CDK4 induces DDLPS tumour potency in transformed human BMSCs by accelerating cell growth and migration and blocking adipogenetic potential incooperation with multiple genetic factors. G., Bonnet, D. and Janes, S. M. (2007). Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 25, 1586-94. . et al. (2014). Immunohistochemical toolkit for tracking and quantifying xenotransplanted human stem cells. Regen Med 9, 437-52. Ballinger, M. L., Goode, D. L., Ray-Coquard, I., James, P. A., Mitchell, G., Niedermayr, E., Puri, A., Schiffman, J. D., Dite, G. S., Cipponi, A. et al. (2016).
Introduction
Liposarcoma (LPS) is one of the most frequently occurring types of soft tissue sarcoma in adults (Dodd, 2012) . According to histological characteristics, LPS consists of three categories: well-differentiated or dedifferentiated, myxoid/round cell, and pleomorphic LPSs (Dodd, 2012) . Well-differentiated (WD) or dedifferentiated (DD)LPS is the most common subtype and contains supernumerary ring and/or giant rod chromosomes formed by amplification of chromosome 12q13-15,which contains several hundred genes, including MDM2 and CDK4 (Pedeutour et al., 1999) . Amplification and overexpression of MDM2 and CDK4 are generally accepted as current WDLPS/DDLPS diagnostic criteria (Barretina et al., 2010; Italiano et al., 2009; Song et al., 2017) .
MDM2 inhibits tumour suppressor p53 and is overexpressed in numerous cancers (Toledo and Wahl, 2006) . MDM2 functions as aubiquitin ligase that targets p53 through the proteasomal degradation pathway, as well as participates in its own auto-degradation to prohibit MDM2 activity, inhibiting p53 during periods of cellular stress (Choi et al., 2018; Stommel and Wahl, 2004) . CDK4 forms a complex with cyclin D, which then phosphorylates pRB. This prevents E2F from interacting with phosphorylated pRB, which causes the cell cycle to progress into the G1-S transition and increases cell proliferation (Day et al., 2009; Harbour et al., 1999; Shim et al., 2010) . Knockdown of MDM2 or CDK4 decreased cell proliferation in DDLPS cells (Barretina et al., 2010) . Despite their potency as driving factors, it remains unclear whether MDM2 and CDK4 induce WDLPS/DDLPS tumorigenesis.
It has been well-established that genetic manipulation of important tumour suppressor genes and oncogenes induces transformation of human BMSCs to various sarcomas in vitro or in vivo (Kirsch et al., 2007; Rodriguez et al., 2012; Rosland et al., 2009; Torsvik et al., 2010; Wang et al., 2005) . However, studies have failed to model sarcomagenesis through the expression of fusion oncogenes in human mesenchymal stem cells (MSCs) (Cironi et al., 2009; Riggi et al., 2008) . Recently, robust evidence showed that expression of the FUS-CHOP fusion protein may initiate myxoid liposarcoma in transformed human BMSCs (Rodriguez et al., 2013) . Therefore, we examined whether MDM2 and/or CDK4 produce WDLPS/DDLPS using transformed human BMSCs. 
Results

Transformed human BMSCs retain their stemness characteristics
To examine whether co-overexpression of MDM2 and CDK4 drives WDLPS/DDLPS tumorigenesis, we used two transformed BMSCs (2H and 5H cells) containing two to five different oncogenic mutations ( Fig. 1A ) (Rodriguez et al., 2013) . These oncogenic hits include the following: ) ectopic overexpression of human telomerase reverse transcriptase (hTERT), ) TP53 degradation by expression of E6 antigen of human papillomavirus-16 (HPV-16), ) RB family inactivation by expression of E7 antigen of HPV-16, ) c-MYC stabilization by expression of small T antigen of Simian virus 40 (SV40), and ) activation of mitogenic signal by expression of HRAS v12 . The E6 antigen of HPV-16mediates TP53 degradation via the proteasomal degradation pathway as observed in MDM2. However, E6 and MDM2 are regulated through well-established distinct mechanisms (Camus et al., 2003; Camus et al., 2007) . Therefore, none of the five oncogenic aspects were directly relevant to WDLPS/DDLPS. We examined the characteristics of 2H and 5H cells and compared them to non-transformed BMSCs. The 2H and 5H cells expressed cell surface makers, such as CD105 (human mesenchymal stromal cell marker; positive) and CD34 (hematopoietic progenitor cell marker; negative), which is consistent with BMSCs ( Fig. 1B) . However, the morphology of 2H and 5H cells differed from that of BMSCs, which are characterized by spindle-shaped morphology that includes a large cell body with a long and thin tails. Both 2H and 5H cells were shorter and thicker than BMSCs, while 5H cells were much shorter and more radial than 2H cells. The 2H and 5H cells showed sustained mRNA expression of stemness genes, such as NANOG and OCT-4, under an adipogenesis-inducing medium, although 5H cells showed lower expression than 2H cells (Fig. 1C) . Additionally, the 2H and 5H cells showed up-regulation of NANOG and OCT-4 only when cultured in DMEM medium ( Fig. S1 ). 2H and 5H cells were maintained in a manner in which they retained their ability to differentiate into adipocytes in response to adipogenesis medium, despite the low potency rate compared to BMSCs (Fig. 1D ). These findings suggest that 2H and 5H cells retained the characteristics of BMSCs.
Co-overexpression of MDM2 and CDK4 synergistically drives tumorigenic phenotypes of transformed human BMSCs
To establish cells co-overexpressing MDM2 and CDK4, 2H and 5H cells were infected with either LacZ-(β-galactosidase, control) or MDM2-and/or CDK4-expresssing lentiviral particles. Expression of the transcript and protein of MDM2 and/or CDK4 was confirmed by immunoblotting ( Fig. 2A ) and qRT-PCR ( Fig. S2 ). To evaluate the expression levels of MDM2 and/or CDK4 in transduced 2H and 5H cells, we compared the expression to two representative liposarcoma cell lines, LIPO-863B (WDLPS) and LP6 (DDLPS). MDM2 protein expression was increased by 1.06-and 1.37-fold and 2.63-and 4.14-fold in 2H and 5H cells, respectively, and the fold-change 2.32-3.24 in LIPO-863B cells. In addition, MDM2
mRNA expression values were observed at biological levels, with fold-changes of 0.29 or 0.62 in 2H and 5H cells compared to in LIPO-863B cells ( Fig. S2 ). For CDK4 expression, transduced 2H and 5H cells showed more than two-fold higher expression than in both LP6 and LIPO-863B cells ( Fig. 2A ). Morphologically, both 2H and 5H cells co-overexpressing MDM2 and CKD4 were much longer and thinner than those solely expressing MDM2, CDK4, or LacZ (Fig. 2B ).
We next examined whether co-overexpression of MDM2 and CDK4 accelerates tumorigenic potential in transformed cells. In both 2H and 5H cells, co-overexpression of MDM2 and CDK4 significantly increased cell proliferation ( Fig. 3A and 3C) , anchorage-independent cell growth ( Fig. 3B and 3D ), and cell migration ( Fig. 3E ) compared to sole expression of MDM2 or CDK4. Interestingly, 5H cells only expressing MDM2 showed significantly increased anchorage-independent cell growth ( Fig. 3D ) and activated cell mobility ( Fig. 3E ), but not cell proliferation ( Fig. 3C ) relative to cells expressing CDK4 alone. These results indicate that co-overexpression of MDM2 and CKD4 plays a key role in tumorigenesis when transformed in BMSCs.
Co-overexpression of MDM2 and CDK4 blocks differentiation potential of adipogenesis
To examine whether overexpression of MDM2 and CDK4 alters adipogenesis potential, we first performed Oil Red O staining after culture in adipogenic induction medium. 2H-MDM2 & CDK4 cells displayed small amounts of lipid droplets compared to 2H-LacZ cells and became longer and thinner than cells expressing only MDM2 or CDK4 (Fig. 4A ). 5H-MDM2 and 5H-MDM2&CDK4 cells showed reduced positivity of Oil Red O staining and contained stellar cell bodies compared to both 5H-LacZ and 5H-CDK4 cells (Fig. 4C ). Next, we analysed the expression levels of genes serially induced during adipogenesis by real-time PCR: C/EBPβ (in the early step), C/EBPα and PPARγ (from the middle to late steps), C/SREBP1 (full step), and ADIPSIN and LPL (late step) (Cowherd et al., 1999) . As shown in Fig. 4B , cells expressing only MDM2 or co-overexpressing MDM2 and CDK4 showed relatively down-regulated expression levels compared to that in both 2H-LacZ and 2H-CDK4 cells. Their expression levels were similar to those of LP6 cells except for C/EBPβ. Compared to 5H-LacZ cells, MDM2 and/or CDK4 expression led to decreased expression of all genes except C/EBPβ and PPARγ. Notably, co-overexpression of MDM2 and CDK4 decreased the expression of all adipogenesis-related genes, showing similar levels in LP6 cells ( Fig. 4D ). Taken together, these data suggest that co-expression of MDM2 and CDK4 blocks the differentiation of adipogenesis from the early to late stages.
Co-overexpression of MDM2 and CDK4 in transformed human BMSCs results in the development of proliferative DDLPS tumours in vivo
To verify in vivo tumorigenic potential, nude mice were subcutaneously inoculated with 2H and 5H cells co-overexpressing MDM2 and CDK4. 2H cells did not develop into tumours, regardless of co-expression of MDM2 and CDK4 (Fig. 5A ). Consistent with a study by Rodriguez et al., 5H-LacZ cells formed tumours with high penetrance (4/5, Fig. 5A ) (Rodriguez et al., 2013) . However, the 5H-MDM2&CDK4 cells developed larger tumours than those observed from the LacZ control ( Fig. 5B and 5C ). In addition, LP6 cells showed much more aggressive tumour formation compared to 5H-MDM2 and CDK4 cells in vivo despite their low growth potency in vitro ( Fig. 5B and 5C, and Fig. S3 ).
We next performed histological analysis of 5H cell-derived tumours including the LIPO-863 and LP6 xenograft models. The 5H-MDM2 and CDK4 cell-derived tumours were immunostained and found to be strongly positive for MDM2 and CDK4, while tumours derived from 5H-LacZ were not ( Fig. 6A ). Although relatively high background was observed, their intensity levels were similar to those of LP6 cell-derived tumours (Fig. 6A ).
The 5H-MDM2 and CDK4 cell-derived tumours exhibited more proliferative features with high cellularity compared to 5H-LacZ-derived tumours ( Fig. 6B ). Moreover, these tumours morphologically resembled LP6-derived tumours displaying large nuclear cells with variable sizes dispersed within a fibrous matrix, but not LIPO-863B-derived tumours which were composed of mature adipocytic cells with diverse size, associated with a variable number of atypical stromal cells ( Fig. 6B and Fig. S4 ). In addition, tumours from 5H-MDM2&CDK4 cells showed a small portion of lipoblast cells but they were not immunostained with KU80
reported as a marker of human cells; therefore, these lipoblast cells may not be derived from 5H-MDM2&CDK4 cells ( Fig. S5) (Allard et al., 2014) . These findings indicate that co-overexpression of MDM2 and CDK4 in 5H cells with five additional oncogenic mutations can result in the development of proliferative DDLPS in vivo.
Discussion
WDLPS/DDLPS is characterized by amplification and overexpression of MDM2 and CDK4.
However, several other oncogenes, such as HMGA2, c-JUN, ZIC1, and others, have been reported to contribute to tumorigenesis and disease progression of WDLPS/DDLP (Barretina et al., 2010; Brill et al., 2010; Italiano et al., 2009; Italiano et al., 2008; Mariani et al., 2007; Sioletic et al., 2014; Snyder et al., 2009) . Although amplification and overexpression of MDM2 and CDK4 are hallmark events of WDLPS/DDLPS, whether MDM2 and CDK4 drive WDLPS/DDLPS tumorigenesis remains unclear. Therefore, it is necessary to evaluate whether amplification and overexpression of MDM2 and CDK4 is a critical event for WDLPS/DDLPS development. We addressed this question by establishing a corresponding xenograft.
Human BMSCs have not been shown to undergo spontaneous transformation in vitro, other than in few cases in which BMSC-injected patients later developed osteosarcoma (Aguilar et al., 2007; Berger et al., 2008; Bernardo et al., 2007; Bielack et al., 2003) . In addition, sarcomagenesis models expressing the fusion proteins EWS-FLI1 or SYT-SSX1 in human BMSCs failed to generate tumour phenotypes (Cironi et al., 2009; Riggi et al., 2008) . including TP53 and RB (Ballinger et al., 2016) . They also showed that multiple mutations are significantly correlated with poorer tumour-free survival. Here, 2H cells with two oncogenic hits, TERT and HPV-16 E6 (TP53 degradation), did not develop into tumours, while 5H cells harbouring three additional oncogenic hits, HPV-16 E7 (RB family inactivation), SV40-ST (c-MYC stabilization), and HRAS v12 (mitogenic signal activation), generated tumours in vivo.
Our findings suggest that TERT and HPV-16 E6 may not cooperate with MDM2 and CDK4 for BMSCs to develop into WDLPS/DDLPS, but HPV-16 E7, SV40-ST, or HRAS v12 may be required to contribute to the transformation of BMSCs.
Although histological analysis of 5H-MDM2 and CDK4-derived tumours could not be clearly classified as DDLPS, co-overexpression of MDM2 and CDK4 played a key role of tumorigenesis during the transformation of BMSCs under cooperation conditions with multiple genetic alterations. DDLPS is thought to develop from WDLPS after a long duration, which was confirmed by the detection of exclusively low-grade dedifferentiated components, its specific genomic profile compared to WDLPS, and that most DDLPS occurs de novo (90%); therefore, DDLPS now be identified in the absence of WDLPS (Chibon et al., 2002; Ghadimi et al., 2011; Lahat et al., 2008) . Moreover, our in vivo experiments showed that DDLPS tumour potency may be induced without the WDLPS component. To comprehensively understand the mechanism of WDLPS/DDLPS development, characterization of both germline and somatic genetic alterations is needed using a massive next-generation sequencing approach in different large cohorts of each WDLPS or DDLPS.
Although cell proliferation and differentiation are regarded as mutually exclusive events, cross-talk has been reported between both processes during adipogenesis (Fajas, 2003) . 
Previous reports suggested that MDM2 promotes adipocyte differentiation through CREB-
Materials and Methods
Cell lines and reagents
Transformed 2H and 5H human bone marrow stem cells and the LIPO-863B and LP6 cell lines were kindly provided by Dr. Pablo Menendez, Dina Lev, and Jonathan A Fletcher, respectively (Peng et al., 2011; Riggi et al., 2008; Sioletic et al., 2014) . The cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% foetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and 1% antibiotic-antimycotic (Gibco) at 37°C and in 5% CO₂. Mycoplasma contamination was not detected in any cell.
RT-PCR
cDNA was generated from total RNA using SuperScript III Transcriptase according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Quantitative reverse transcription (qRT)-polymerase chain reaction (PCR) amplification of stemness-or adipogenesis-related genes was conducted using probes and primers with the Universal Probe Library System (Roche, Basel, Switzerland). MDM2 amplification was performed using the following primer pair: Forward, (5′-ACCTCACAGATTCCAGCTTCG); Reverse, (5′-TTTCATAGTATAAGT GTCTTTTT). HPRT1 was used as a reference gene, and the ratio of each gene to HPRT1was calculated for relative quantification of the expression level of each gene.
Immunoblotting, immunocytochemistry, immunohistochemistry, and fluorescenceactivated cell sorting (FACS)
Equal amounts of protein were subjected to SDS-PAGE on an 8.5% gel before being transferred to a nitrocellulose membrane (Pall Corporation, Port Washington, NY, USA). The membrane was incubated with primary anti-MDM2, CDK4, and β -ACTIN (diluted 1:1,000 in 5% non-fat milk, Santa Cruz Biotechnology, Dallas, TX, USA) and FLAG (diluted 1:1,000 in 5% non-fat milk, Sigma-Aldrich, St. Louis, MO, USA) antibodies, and then washed (30 min) with T-BST. The membrane was incubated with horseradish peroxidase-conjugated secondary goat anti-rabbit or anti-mouse antibodies (diluted 1:2,000 in 5% non-fat milk, Abcam) for 1h, followed by 30 min of washing with T-BST. Signals were detected using ECL solution (Thermo Fisher Scientific). Four-micrometre-thick sections from formalin- 
Generation of stable cell line over-expressing MDM2 and/or CDK4
The full-length cDNAs of MDM2 or CDK4 were generated from a cDNA library of human bone marrow stem cells. The PCR products were cloned into the N-terminal p3XFLAG-CMV-10 vector (Sigma-Aldrich). We confirmed the full sequence of wild-type MDM2 and CDK4 by the Sanger sequencing method. Full-length 3XFLAG-MDM2 or 3XFLAG-CDK4 were cloned into the gateway entry vector pCR8/GW/Topo (Invitrogen), and then subcloned into pLenti6.3/V5-DEST (Invitrogen). Full-length sequences of 3XFLAG-MDM2 or 3XFLAG-CDK4 were validated by Sanger sequencing. pLenti6.3/3XFLAG-MDM2 or 3XFLAG-CDK4 expression vectors were transfected into 293FT cells using ViraPower Packaging Mix (Invitrogen) to produce lentivirus expressing MDM2 or CDK4. After 48h, lentiviral supernatants were harvested and transduced into 2H and 5H cells in the presence of 8µg/mL of polybrene. Transduced cells were grown in DMEM complete medium for48hafterinfection, and then the medium was replaced with medium containing blasticidin (5µg/mL) after 24h. Cells were selected for 2 weeks using selective medium. Stable expression of MDM2 or CDK4 was confirmed by qRT-PCR and immunoblotting.
Cell proliferation and migration assays and soft agar assay
The cell proliferation assay was performed using an EZ-CYTOX kit (Daeil Lab Service, Seoul, Korea) according to the manufacturer's instructions. Cells were plated in 96-well plates (3 ×10 2 cells/well). The 96-well plates were incubated with EZ-CYTOX reagent for 3 hours at 37°C after 1 and 2 days. Twenty-four-well trans-well chambers (Corning Costar, Corning, NY, USA) with 8-μm polycarbonate membrane filters were used to determine migration ability. For this assay, 5 × 10 4 cells were seeded into the upper chamber in DMEM without FBS. The lower chamber contained 700 μ L of DMEM containing 10% FBS. The trans-well chamber was incubated at 37°C in 5% CO 2 . After 24 h of incubation, nonmigrating cells on the upper filter surface were removed with a cotton swab and the migrated cells were stained with 0.5% crystal violet. Cells were seeded into 24-well plates with the appropriate concentrations of agarose (0.5% for base and 0.3% for top) to form colonies in 3 weeks. Colonies were stained with crystal violet (0.5% w/v) and counted using a microscope.
Adipogenic differentiation
BMSCs and 2H and 5H cells were seeded onto a 6-well plate in DMEM medium, and then replaced with adipogenic differentiation medium (StemPro Adipogenic Differentiation Kit, Invitrogen) every 3-4 days. After 10 days, the cells were stained with an Oil Red O staining kit (Lifeline, Frederick, MD, USA) according to the manufacturer's instructions.
Mouse xenograft modelling
This study was reviewed and approved by the Institutional Animal Care and Use Committee of Samsung Biomedical Research Institute (SBRI, Seoul, Korea). SBRI is an Association for Assessment and Accreditation of Laboratory Animal Care International accredited facility and abides by the Institute of Laboratory Animal Resources guide (No. 20160108001).
Female nude mice were injected subcutaneously with 2H, 5H, LIPO-863B, or LP6 (5×10 6 ) cells. After the indicated number of days, tumour diameter was measured using a digital calliper two or three times per week, and tumour sizes were estimated using the following formula: (3.14/6) (length×width 2 ). 
Figure legends
